Get the Stockscreener App
0.903
3.48%
0.0304
After Hours:
.90
-0.003
-0.33%
Jasper Therapeutics Inc stock is traded at $0.903, with a volume of 680.20K.
It is up +3.48% in the last 24 hours and down -7.77% over the past month.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
See More
Previous Close:
$0.8726
Open:
$0.88
24h Volume:
680.20K
Relative Volume:
1.73
Market Cap:
$25.28M
Revenue:
-
Net Income/Loss:
$-75.80M
P/E Ratio:
-0.1963
EPS:
-4.6004
Net Cash Flow:
$-77.17M
1W Performance:
+6.22%
1M Performance:
-7.77%
6M Performance:
-46.88%
1Y Performance:
-81.46%
1-Day Range:
$0.87
$1.0199
1-Week Range:
$0.7651
$1.0199
52-Week Range:
$0.623
$7.19
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
(650) 549-1400
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
0.903 | 24.43M | 0 | -75.80M | -77.17M | -4.6004 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Resumed | UBS | Neutral |
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Jul-08-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-07-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-13-25 | Initiated | UBS | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Sep-09-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-08-24 | Initiated | BTIG Research | Buy |
| Jun-27-24 | Initiated | Stifel | Buy |
| May-06-24 | Initiated | H.C. Wainwright | Buy |
| Apr-03-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-18-24 | Initiated | TD Cowen | Outperform |
| Aug-11-23 | Initiated | CapitalOne | Overweight |
| Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Credit Suisse | Outperform |
| Oct-21-21 | Initiated | William Blair | Outperform |
| Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
Jasper Therapeutics Announces Board Resignation and Committee Change - TipRanks
Christian Nolet resigns from Jasper Therapeutics board; Svetlana Lucas joins Audit Committee - TradingView
Jasper Therapeutics (NASDAQ: JSPR) reports director exit and audit change - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Jasper Therapeutics, Inc.Class A Common Stock (NQ: JSPR - The Chronicle-Journal
Jasper Therapeutics stock maintains outperform rating at Citizens By Investing.com - Investing.com Canada
JSPR Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Hold Rating, Cuts Target Price to $3 - Moomoo
JSPR Maintained by RBC Capital -- Price Target Lowered to $3.00 - GuruFocus
RBC Cuts Price Target on Jasper Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk - Moomoo
TD Cowen Downgrades Jasper Therapeutics(JSPR.US) to Hold Rating - Moomoo
TD Cowen downgrades Jasper Therapeutics stock rating to Hold By Investing.com - Investing.com Canada
Jasper Therapeutics, Inc. Stock 12‑Month Price Target Cut to $9.08, Implies 847% Upside - TradingView
TD Cowen downgrades Jasper Therapeutics (JSPR) - MSN
Jasper Therapeutics shares rise 5% on clinical updates despite Q4 loss - MSN
Jasper Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
[10-Q] Jasper Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Jasper drug sees 67% complete response in CSU trial update - Stock Titan
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Jasper Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Jasper Therapeutics (NASDAQ: JSPR) cuts Q1 2026 loss but flags funding risk - Stock Titan
Jasper Therapeutics (JSPR) price target decreased by 13.33% to 7.73 - MSN
Morgan Stanley units report sub‑5% stakes in Jasper Therapeutics (JSPR) - Stock Titan
TradingKey - TradingKey
The strategic priorities reflected in Jasper Therapeutics (JSPR) results | Q4 2025: Profit SurprisesRevenue Growth - Newser
[SCHEDULE 13G/A] Jasper Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Goldman Sachs (JSPR) joint 13G/A: 128,862 shares, 0.5% stake - Stock Titan
Executive pay and board changes at Jasper Therapeutics (JSPR) - Stock Titan
Jasper Shares Surge Following Encouraging Early Asthma Trial Data - MSN
12 Health Care Stocks Moving In Tuesday's After-Market SessionActuate Therapeutics (NASDAQ:ACTU), Celu - Benzinga
Why UBS started Jasper Therapeutics (JSPR) at neutral despite progress in briquilimab - MSN
Acute Myeloid Leukemia Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma, Syros Pharma, TC Biopharm - Barchart.com
Will Jasper Therapeutics (JSPR) Stock Fall Further | Price at $0.78, Up 10.73%Market Profile - Newser
What is the biggest uncertainty for Jasper Therapeutics (JSPR) Stock | Price at $0.67, Up 0.87% - Newser
Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7 - Insider Monkey
JSPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN) - The Globe and Mail
12 Health Care Stocks Moving In Thursday's After-Market SessionBullfrog AI Hldgs (NASDAQ:BFRG), CDT Eq - Benzinga
Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway - The Globe and Mail
Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI - TipRanks
Citizens reiterates Jasper Therapeutics stock rating on CEO change By Investing.com - Investing.com Australia
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Jasper Therapeutics Inc Stock (JSPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lucas Svetlana | Director |
Sep 22 '25 |
Buy |
2.43 |
20,000 |
48,600 |
20,000 |
| MARTELL RON | President and CEO |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
74,118 |
| Shizuru Judith Anne | Director |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
156,901 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):